What is the main purpose of this 8-K/A filing?

This filing serves as an amendment to a previous 8-K filing to provide investors with the necessary financial statements and pro forma information related to Boston Scientific Corporation's acquisition of Guidant Corporation. It includes Guidant's financial results for the first quarter of 2006 and pro forma combined financials reflecting the acquisition.

What was the total cost of the Guidant acquisition for Boston Scientific?

The aggregate consideration paid by Boston Scientific for Guidant approximated $27.5 billion. This consisted of approximately 577 million shares of Boston Scientific's common stock and approximately $14.5 billion in cash. Additional interest payments were also made to Guidant shareholders.

What happened to Guidant's vascular intervention and endovascular businesses?

Prior to the closing of the Boston Scientific acquisition, Abbott Laboratories acquired Guidant's vascular intervention and endovascular businesses. This transaction involved an initial cash payment of $4.1 billion to Guidant, along with potential future milestone payments and the assumption of certain liabilities by Abbott.

What is the significance of the pro forma financial information provided?

The unaudited pro forma financial information presents a combined view of Boston Scientific and Guidant as if the acquisition and the related Abbott transaction had occurred at an earlier date (January 1, 2005, for the income statement and March 31, 2006, for the balance sheet). This allows investors to better understand the potential financial impact and scale of the combined entity, including key adjustments like goodwill and identifiable intangible assets, though it is important to note this is a preliminary estimate.

BSX 8-K: Acquisitions & Dispositions

Summary

This filing is an amendment (8-K/A) by Boston Scientific Corporation (BSX) to its prior filing on April 26, 2006. The primary purpose of this amendment is to provide updated financial information related to the acquisition of Guidant Corporation. Specifically, it includes the unaudited condensed consolidated financial statements of Guidant Corporation for the three months ended March 31, 2006, and unaudited pro forma combined financial information for Boston Scientific and Guidant as of and for the same period. The filing details the significant financial impact of the Guidant acquisition, including the transaction's consideration, the divestiture of certain Guidant businesses to Abbott Laboratories, and the pro forma combined financial statements reflecting these events. For investors, this provides crucial details on the financial scale and expected integration of the newly acquired Guidant operations into Boston Scientific's business.

Key Highlights

1Amendment to a prior 8-K filing to include supplemental financial information regarding the Guidant acquisition.
2Includes unaudited condensed consolidated financial statements for Guidant Corporation for the three months ended March 31, 2006.
3Presents unaudited pro forma combined financial information for Boston Scientific and Guidant for the three months ended March 31, 2006.
4Details the consummation of the acquisition of Guidant Corporation by Boston Scientific on April 21, 2006, with a total consideration of approximately $27.5 billion.
5Notes the divestiture of Guidant's vascular intervention and endovascular businesses to Abbott Laboratories prior to the closing of the Boston Scientific acquisition.
6The pro forma financial statements reflect the combined entity post-acquisition and post-divestiture, giving effect to the merger, the Abbott transaction, and associated financing.
7Preliminary purchase price allocation indicates significant amounts assigned to identifiable intangible assets and goodwill.

BOSTON SCIENTIFIC CORP 8-K/A Report, Acquisition Completed (May 31, 2006)

Summary

Key Highlights

Frequently Asked Questions